Favipiravir Tablets

[otw_shortcode_tabslayout tabs=”10″ tab_1_title=”Indications” tab_1_content=”This product is intended primarily for the treatment of new or recurrent influenza in adults (only when other anti-influenza viral medications have failed or are not effective).” tab_2_title=”Dosage” tab_2_content=”The usual adult course of treatment is 5 days; on day 1, 1 dose of 1600 mg twice a day; from day 2 to day 5, 1 dose of 600 mg twice a day, administered orally.” tab_3_title=”Adverse Reactions” tab_3_content=”Not yet known.” tab_4_title=”Contraindications” tab_4_content=”Not yet specified.” tab_5_title=”Precautions” tab_5_content=”Unclear.” tab_6_title=”Interactions” tab_6_content=”Drug interactions may occur if used with other drugs; consult your doctor or pharmacist for details.” tab_7_title=”Storage” tab_7_content=”Sealed.” tab_8_title=”Ingredients” tab_8_content=”The main ingredient of this product is famipiravir.” tab_9_title=”Pharmacology and Toxicology” tab_9_content=”Famipiravir is an antiviral drug. It inhibits RNA polymerase.” tab_10_title=”Properties” tab_10_content=”This product is a light yellow film-coated tablet with a white to light yellow core after removal of the film coating.”] [/otw_shortcode_tabslayout]